Please login to the form below

Not currently logged in
Email:
Password:

Covance and Sihuan Pharma partner on portfolio development

Will collaborate on preclinical and clinical stages

Covance 

LabCorp's Covance and Shandon XuanZhu, a subsidiary of Chinese R&D firm Sihuan Pharmaceutical, have announced a partnership on preclinical and clinical portfolio development.

As part of the alliance, Covance will support the global development of Sihuan Pharmaceutical's drug candidate pipeline, which consists of multiple compounds that address unmet needs across therapeutics areas including cardiovascular, metabolic, infectious disease, oncology and urology.

Honggang Bi, corporate VP and general manager of China at Covance, said: “This agreement is the first of its kind signed with a partner in the Asia Pacific region, and Covance looks forward to collaborating with Sihuan Pharmaceutical in its efforts to potentially bring global filing strategies to realisation.” 

“With multiple compounds in its development pipeline, Sihuan Pharmaceutical is a promising pharmaceutical company to watch for groundbreaking new therapies.”

Specifically, Sihuan will be provided with drug development and regulatory expertise, particularly in efforts to achieve dual or multiple filings for regulatory approvals such as investigational new drug (IND) applications and new drug applications (NDA) in China and internationally.

Dr Frank Wu, chief scientific officer of Sihuan Pharmaceutical, commented: “The partnership is another milestone for our international collaboration and R&D team, which will enable us to accelerate the development of our pipeline, in turn helping to bring treatments to multiple markets faster, a key point of differentiation in the Chinese pharmaceutical industry.”

LabCorp announced the acquisition of full-service drug development firm Covance last November, with the deal being valued at $5.6bn.

Article by
Kirstie Pickering

2nd April 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics